Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ROS1 status confers therapeutic sensitivity to Entrectinib in patients with Non-Small Cell Lung Cancer.
This statement is based on a regulatory approval from the Health Canada:
ROZLYTREK (entrectinib) is indicated for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.